Susceptibility Vessel Sign in Relation With Time From Onset to Magnetic Resonance Imaging.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
05 2021
Historique:
pubmed: 9 4 2021
medline: 5 1 2022
entrez: 8 4 2021
Statut: ppublish

Résumé

In acute ischemic stroke, the susceptibility vessel sign (SVS) on T2* MR-sequence witnesses the red blood cell content of the clot. Although clot composition strongly depends on its age in vitro, the relationship between SVS and time has not been studied. In this study, we evaluated whether the presence of SVS was related to the time from symptom onset. We retrospectively analyzed our institutional registry of patients with acute stroke between November 2007 and June 2018. We included patients with an ischemic stroke confirmed by diffusion-weighted imaging magnetic resonance imaging within 8 hours from symptom onset caused by M1 or M2 occlusion and with interpretable T2*-weighted images. We compared clinical and imaging variables among SVS+ and SVS− patients. Time from onset was split into tertiles. Independent markers of SVS+ were identified using multivariable logistic regression. The probability of being SVS+ given time from symptoms onset was modeled using Probit regression. Among the 608 patients included, 433 (71.2%) were SVS+. The odds of being SVS+ increased with time from symptom onset (P trend=0.005). In the multivariable analysis, factors independently associated with a SVS+ were symptom onset to magnetic resonance imaging ([130–180 min] odds ratio [OR], 1.62 [95% CI, 1.03–2.53]; [>180 min] OR, 3.14 [95% CI, 1.92–5.12]), type of magnetic resonance imaging-scanner (OR, 2.83 [95% CI, 1.82–4.41]), cardioembolic cause (OR, 1.51 [95% CI, 1.02–2.24]), and baseline National Institutes of Health Stroke Scale (OR, 1.05 [95% CI, 1.01–1.08]). The probability of being SVS+ increased with time from symptom onset (P=0.004): around 60% at 1 hour, 70% at 3 hours, 80% at 6 hours, and 90% at 8 hours. In acute ischemic stroke, the presence of SVS depends on time from onset to imaging.

Sections du résumé

Background and Purpose
In acute ischemic stroke, the susceptibility vessel sign (SVS) on T2* MR-sequence witnesses the red blood cell content of the clot. Although clot composition strongly depends on its age in vitro, the relationship between SVS and time has not been studied. In this study, we evaluated whether the presence of SVS was related to the time from symptom onset.
Methods
We retrospectively analyzed our institutional registry of patients with acute stroke between November 2007 and June 2018. We included patients with an ischemic stroke confirmed by diffusion-weighted imaging magnetic resonance imaging within 8 hours from symptom onset caused by M1 or M2 occlusion and with interpretable T2*-weighted images. We compared clinical and imaging variables among SVS+ and SVS− patients. Time from onset was split into tertiles. Independent markers of SVS+ were identified using multivariable logistic regression. The probability of being SVS+ given time from symptoms onset was modeled using Probit regression.
Results
Among the 608 patients included, 433 (71.2%) were SVS+. The odds of being SVS+ increased with time from symptom onset (P trend=0.005). In the multivariable analysis, factors independently associated with a SVS+ were symptom onset to magnetic resonance imaging ([130–180 min] odds ratio [OR], 1.62 [95% CI, 1.03–2.53]; [>180 min] OR, 3.14 [95% CI, 1.92–5.12]), type of magnetic resonance imaging-scanner (OR, 2.83 [95% CI, 1.82–4.41]), cardioembolic cause (OR, 1.51 [95% CI, 1.02–2.24]), and baseline National Institutes of Health Stroke Scale (OR, 1.05 [95% CI, 1.01–1.08]). The probability of being SVS+ increased with time from symptom onset (P=0.004): around 60% at 1 hour, 70% at 3 hours, 80% at 6 hours, and 90% at 8 hours.
Conclusions
In acute ischemic stroke, the presence of SVS depends on time from onset to imaging.

Identifiants

pubmed: 33827243
doi: 10.1161/STROKEAHA.120.032198
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1839-1842

Auteurs

Sebastien Soize (S)

Université Caen-Normandie, INSERM UMR-S U1237, Cyceron, Caen, France (S.S., M.G., M.Z., E.T.).
Neuroradiology, Hôpital Maison Blanche, CHU Reims, France (S.S., P.-F.M., T.H., L.P.).

Pierre-François Manceau (PF)

Neuroradiology, Hôpital Maison Blanche, CHU Reims, France (S.S., P.-F.M., T.H., L.P.).

Maxime Gauberti (M)

Université Caen-Normandie, INSERM UMR-S U1237, Cyceron, Caen, France (S.S., M.G., M.Z., E.T.).
Radiology (M.G.), CHU Caen Normandie, France.

Thibault Herbin (T)

Neuroradiology, Hôpital Maison Blanche, CHU Reims, France (S.S., P.-F.M., T.H., L.P.).

Mathieu Zuber (M)

Université Caen-Normandie, INSERM UMR-S U1237, Cyceron, Caen, France (S.S., M.G., M.Z., E.T.).
Neurology, Hôpital Saint-Joseph, Paris, France (M.Z.).

Laurent Pierot (L)

Neuroradiology, Hôpital Maison Blanche, CHU Reims, France (S.S., P.-F.M., T.H., L.P.).

Emmanuel Touzé (E)

Université Caen-Normandie, INSERM UMR-S U1237, Cyceron, Caen, France (S.S., M.G., M.Z., E.T.).
and Neurology (E.T.), CHU Caen Normandie, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH